Opportunity Information: Apply for CDC RFA GH13 1366SUPP15
Apply for CDC RFA GH13 1366SUPP15
- The HHS-CDC in the health sector is offering a public funding opportunity titled "Supporting Laboratory Strengthening Activities in Resource-Limited Countries under the President's Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
- This funding opportunity was created on Jan 15, 2016 and posted on Jan 15, 2016.
- Applicants must submit their applications by Feb 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Supporting Laboratory Strengthening Activities in Resource-Limited Countries under the President's Emergency Plan for AIDS Relief (PEPFAR)" is a CDC cooperative agreement notice released by HHS/CDC primarily to document program intent rather than to invite competition. It was published as an informational Funding Opportunity Announcement (FOA) only, meaning no applications were requested or accepted under this notice. The FOA number is CDC RFA GH13-1366SUPP15, it falls under CFDA 93.067, and it lists an expected single award. Although a closing date of February 15, 2016 appears in the record, the key takeaway is that this posting functioned as a formal public notice rather than an open call for proposals.
Eligibility in this specific notice is effectively restricted to one named entity: the Association of Public Health Laboratories (APHL). That limitation aligns with how some CDC cooperative agreements and supplements are handled when CDC intends to continue or expand work with an established partner that already has the infrastructure, relationships, and technical capacity to carry out highly specialized activities in coordination with country programs and other stakeholders.
Programmatically, the FOA sits under the broader umbrella of PEPFAR and is framed around CDCs role, under the leadership of the U.S. Global AIDS Coordinator, in working with host-country governments and partners to assess needs and design tailored assistance. The approach described is country-specific: CDC works within each host nations strategic plan and partnership framework rather than applying a one-size-fits-all model. In practice, CDC indicates it tends to concentrate on two or three major program areas per country to maximize effectiveness and align investments with the most urgent gaps.
The goals and priorities outlined emphasize both prevention and health system capacity, with laboratories positioned as a backbone function that supports nearly every part of an HIV response. On the prevention side, the FOA highlights expanding confidential counseling and testing services that are linked to evidence-based behavior change interventions, along with strengthening programs that reduce mother-to-child transmission. These activities depend heavily on reliable testing systems, quality assurance, and consistent access to diagnostics, which is where laboratory strengthening becomes essential.
On the care and treatment side, the FOA underscores improving the management of HIV/AIDS and sexually transmitted infections, along with better diagnosis and treatment of opportunistic infections. It specifically points to enhancing laboratory diagnostic capacity as a practical lever for improving clinical care, including for intercurrent diseases that significantly affect people living with HIV, such as tuberculosis. It also references the rollout or initiation of antiretroviral therapy programs, which requires laboratory support for baseline testing, ongoing monitoring, and detection of complications.
A third major focus is strengthening surveillance and national program management by improving countries ability to collect, analyze, and use data. The FOA calls out expanding HIV, STI, TB, and Ebola surveillance programs and strengthening laboratory support that enables surveillance, diagnosis, treatment, and disease monitoring. It also mentions HIV screening for blood safety, signaling an interest not only in patient-level services but also in broader public health protections that rely on dependable laboratory systems and quality management.
The FOA also describes an evidence-building component: developing, validating, and/or evaluating public health programs to improve and better target interventions related to HIV/AIDS, TB, Ebola, and other opportunistic infections. Even though evaluation and program improvement are encouraged, the notice explicitly states that research is not supported by this FOA. In other words, the intent is program implementation and applied evaluation rather than hypothesis-driven research projects.
Another recurring theme is coordination and integration to improve cost efficiency and program performance. CDC notes that grantees may be asked to participate in activities that reflect Global Health Initiative principles, such as using a woman- and girl-centered approach, coordinating strategically across partners to increase impact, leveraging multilateral organizations and global health partnerships, engaging the private sector where appropriate, and encouraging country ownership through investment in country-led plans. The FOA further stresses sustainability through health systems investments, improved metrics and monitoring and evaluation, and the promotion of innovation, with the important constraint that this innovation does not extend to funding research under this particular award.
Finally, the rationale for the opportunity is grounded in the realities of service delivery in resource-limited settings. The FOA points out that providing quality laboratory services and reliable diagnostic testing can be difficult where infrastructure, supplies, trained personnel, and quality systems are constrained. At the same time, it makes the case that high-quality laboratory testing is not optional: it is central to clinical diagnosis, infectious disease surveillance, and informed public health policy. The notice argues that good laboratory practices are cost-effective because they reduce errors and wasted resources, improve the reliability and accuracy of results, strengthen patient care, and increase patient confidence in testing, all of which are critical for sustained engagement in HIV prevention and treatment services.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Supporting Laboratory Strengthening Activities in Resource-Limited Countries under the President's Emergency Plan for AIDS Relief (PEPFAR)."
Which agency released this notice?
This is a CDC cooperative agreement notice released by HHS/CDC.
What is the FOA number for this notice?
The FOA number is CDC RFA GH13-1366SUPP15.
What CFDA number is associated with this opportunity?
This notice falls under CFDA 93.067.
Was this an open funding opportunity that accepted applications?
No. It was published as an informational Funding Opportunity Announcement (FOA) only. The notice states that no applications were requested or accepted under this posting.
What was the purpose of posting this FOA if applications were not accepted?
The posting primarily served to document program intent and provide formal public notice, rather than to invite competition.
Does the notice list a closing date, and what does it mean in context?
A closing date of February 15, 2016 appears in the record, but the key point is that this FOA functioned as an informational notice rather than an open call for proposals.
Who was eligible to receive this award under this specific notice?
Eligibility under this notice was effectively restricted to one named entity: the Association of Public Health Laboratories (APHL).
Why was eligibility limited to a single named entity?
The notice indicates this limitation is consistent with how some CDC cooperative agreements and supplements are handled when CDC intends to continue or expand work with an established partner that already has the infrastructure, relationships, and technical capacity to carry out specialized activities in coordination with country programs and stakeholders.
How many awards were expected under this FOA?
The FOA lists an expected single award.
What larger initiative does this opportunity fall under?
The FOA sits under the broader umbrella of PEPFAR (the President's Emergency Plan for AIDS Relief).
How does CDC describe its role in this work?
CDC describes its role as working under the leadership of the U.S. Global AIDS Coordinator, in partnership with host-country governments and other partners, to assess needs and design tailored assistance.
Is the approach described as standardized across countries?
No. The approach is described as country-specific, with CDC working within each host nation's strategic plan and partnership framework rather than using a one-size-fits-all model.
How does CDC indicate it prioritizes activities within countries?
CDC indicates it tends to concentrate on two or three major program areas per country to maximize effectiveness and align investments with the most urgent gaps.
Why are laboratory systems emphasized in this FOA?
Laboratories are framed as a backbone function supporting nearly every part of the HIV response, including prevention, care and treatment, surveillance, and broader public health protections like blood safety.
What prevention-related activities are highlighted?
The FOA highlights expanding confidential counseling and testing services linked to evidence-based behavior change interventions, and strengthening programs that reduce mother-to-child transmission.
How do laboratory strengthening activities support prevention efforts?
Prevention activities depend on reliable testing systems, quality assurance, and consistent access to diagnostics, which the FOA identifies as core reasons laboratory strengthening is essential.
What care and treatment priorities are described?
The FOA underscores improving the management of HIV/AIDS and sexually transmitted infections, improving diagnosis and treatment of opportunistic infections, and enhancing laboratory diagnostic capacity to improve clinical care.
Does the FOA mention tuberculosis (TB) in relation to HIV programs?
Yes. It specifically notes intercurrent diseases that significantly affect people living with HIV, such as tuberculosis, and points to laboratory diagnostic capacity as a practical lever for improving care.
How is antiretroviral therapy (ART) connected to laboratory strengthening in this notice?
The FOA references rollout or initiation of ART programs and notes that laboratory support is needed for baseline testing, ongoing monitoring, and detection of complications.
What does the FOA say about surveillance and national program management?
A major focus is strengthening surveillance and national program management by improving countries' ability to collect, analyze, and use data, supported by stronger laboratory systems.
Which surveillance areas are explicitly mentioned?
The FOA calls out expanding HIV, STI, TB, and Ebola surveillance programs, and strengthening laboratory support that enables surveillance, diagnosis, treatment, and disease monitoring.
Does the notice address blood safety?
Yes. It mentions HIV screening for blood safety, emphasizing broader public health protections that rely on dependable laboratory systems and quality management.
Does this FOA support research projects?
No. The notice explicitly states that research is not supported by this FOA.
If research is not supported, what type of evidence-related work is mentioned?
The FOA describes developing, validating, and/or evaluating public health programs to improve and better target interventions related to HIV/AIDS, TB, Ebola, and other opportunistic infections. This is framed as applied program evaluation and improvement rather than hypothesis-driven research.
What coordination principles or cross-cutting themes are included?
The FOA emphasizes coordination and integration to improve cost efficiency and program performance, and notes that grantees may be asked to participate in activities reflecting Global Health Initiative principles.
What Global Health Initiative principles are referenced in the notice?
Examples listed include using a woman- and girl-centered approach, coordinating strategically across partners to increase impact, leveraging multilateral organizations and global health partnerships, engaging the private sector where appropriate, and encouraging country ownership through investment in country-led plans.
How does the FOA describe sustainability?
It stresses sustainability through health systems investments, improved metrics and monitoring and evaluation, and promotion of innovation, with the constraint that innovation does not extend to funding research under this award.
What challenges in resource-limited settings does the FOA identify?
The FOA notes that providing quality laboratory services and reliable diagnostic testing can be difficult where infrastructure, supplies, trained personnel, and quality systems are constrained.
Why does the FOA argue that high-quality laboratory testing is essential?
It states that high-quality laboratory testing is central to clinical diagnosis, infectious disease surveillance, and informed public health policy, making it a foundational requirement rather than an optional enhancement.
How does the notice describe the cost-effectiveness of good laboratory practices?
It argues that good laboratory practices reduce errors and wasted resources, improve reliability and accuracy of results, strengthen patient care, and increase patient confidence in testing, supporting sustained engagement in HIV prevention and treatment services.
Browse more opportunities from the same category: Health
Next opportunity: 2016 Ambassadors Fund for Cultural Preservation Large Grants Program
Previous opportunity: ENCODE Data Analysis Center (U24)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH13 1366SUPP15
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH13 1366SUPP15) also looked into and applied for these:
| Funding Opportunity |
|---|
| Integrated HIV Prevention and Health Services for Key and Priority Populations (HIS-KP) Apply for RFA 656 16 000001 Funding Number: RFA 656 16 000001 Agency: USAID-MOZ Category: Health Funding Amount: $20,000,000 |
| Evaluation of Core State Violence and Injury Prevention Program (Core SVIPP) Apply for CDC RFA CE16 1603 Funding Number: CDC RFA CE16 1603 Agency: HHS-CDC-NCIPC Category: Health Funding Amount: $300,000 |
| ENCODE Data Coordinating Center (U24) Apply for RFA HG 16 005 Funding Number: RFA HG 16 005 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Expanding the Encyclopedia of DNA Elements (ENCODE) in the Human and Mouse (UM1) Apply for RFA HG 16 002 Funding Number: RFA HG 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Population-based HIV Impact Assessments in Resource-Constrained Settings under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 140903CONT16 Funding Number: CDC RFA GH14 140903CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Implementing Evidence Based Prevention Intervention for Key Populations in the Republic of Rwanda under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 161602CONT16 Funding Number: CDC RFA GH15 161602CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Building Complex 3-Dimensional in Vitro Human Musculoskeletal and Skin Tissue Models (R43) Apply for RFA AR 17 005 Funding Number: RFA AR 17 005 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Surveillance, Service Data Analysis and Capacity Building to Support Management, Leadership and Sustainability of HIV Programs in Haiti and other Health Initiative under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 152902CONT16 Funding Number: CDC RFA GH15 152902CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Expansion and Strengthening of Clinic-Based HIV Related Services in Haiti under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 153002CONT16 Funding Number: CDC RFA GH15 153002CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Research and Technical Assistance for Public Health Intervention Supporting the National Blood Safety Program in the Implementation and Expansion of Blood Safety Activities in the Republic of Haiti under the President's Emergency Plan for AIDS Relief Apply for CDC RFA GH12 125105CONT16 Funding Number: CDC RFA GH12 125105CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strengthening Clinical Services for Men Who have Sex with Men, Transgender, and Bisexual Populations Living with HIV/STI in the Dominican Republic under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 162602CONT16 Funding Number: CDC RFA GH15 162602CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Building Capacity for a Sustainable, Country-led Response to the HIV/AIDS Epidemic in Guyana: A Technical Assistance Support Model to the Guyana Ministry of Health (MOH) under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 152502CONT16 Funding Number: CDC RFA GH15 152502CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Increasing the Capacity of the Government of Suriname to expand Coordinated HIV Prevention, Strategic Information, and Laboratory Programs under the President’s Plan for AIDS Relief Apply for CDC RFA GH12 120705CONT16 Funding Number: CDC RFA GH12 120705CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Promoting Adolescent Health through School-Based HIV/STD Prevention and School-Based Surveillance Apply for CDC RFA PS13 130804CONT16 Funding Number: CDC RFA PS13 130804CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strengthening and Enhancing National HIV/AIDS Prevention, Diagnosis, Care, Treatment, Monitoring and Surveillance of Communicable and Non-communicable Diseases with the Ministry of Health in the Republic of Haiti under the President's Emergency Plan Apply for CDC RFA GH15 152702CONT16 Funding Number: CDC RFA GH15 152702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Noise-Induced Synaptopathy in the Human Auditory System (R01) Apply for RFA DC 17 002 Funding Number: RFA DC 17 002 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| Increase Access to Comprehensive HIV/AIDS Prevention, Care and Treatment Services in the Democratic Republic of Congo under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 152102CONT16 Funding Number: CDC RFA GH15 152102CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 131004CONT16 Funding Number: CDC RFA GH13 131004CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Comprehensive High-Impact HIV Prevention Projects for Community-Based Organizations Apply for CDC RFA PS15 150202CONT16 Funding Number: CDC RFA PS15 150202CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Building Capacity of the Public Health System to Improve Population Health through National, Nonprofit Organizations—finanaced in part by 2016 Prevention and Public Health Fund Apply for CDC RFA OT13 130204CONT16 Funding Number: CDC RFA OT13 130204CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH13 1366SUPP15", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.